Searchable abstracts of presentations at key conferences in endocrinology

ea0081p176 | Pituitary and Neuroendocrinology | ECE2022

Antagonist of growth hormone-releasing hormone (GHRH) inhibits SARS-CoV-2 Spike protein-induced inflammation in macrophages and PBMCs

Granato Giuseppina , Gesmundo Iacopo , Lopatina Tatiana , Felice Brizzi Maria , Victor Schally Andrew , Granata Riccarda

Macrophages play essential roles in the immune defence and their hyperactivation has been implicated in epithelial damage in acute respiratory distress syndrome (ARDS), commonly observed in severe COVID-19 patients. In these cells, SARS-CoV-2 spike (S) protein triggers aberrant production of pro-inflammatory cytokines like interleukin-1 beta (IL-1β), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), as well as reactive oxygen species (ROS) and matrix meta...

ea0070aep683 | Pituitary and Neuroendocrinology | ECE2020

Antitumor effects of growth hormone-releasing hormone (GHRH) antagonists in ACTH- and GH-secreting pituitary neuroendocrine tumor cell lines

Fanciulli Alessandro , Gesmundo Iacopo , Gamba Giacomo , Maria Clara Alvarez Villamarin , Dieguez Carlos , Zatelli Chiara , Cannavò Salvatore , Grottoli Silvia , Arvat Emanuela , Castaño Justo P. , Luque Raùl M. , Cai Renzhi , Sha Wei , Victor Schally Andrew , Granata Riccarda

Pituitary neuroendocrine tumors (PitNETs) are mostly benign lesions originating from the anterior pituitary and represent 10–15% of all the intracranial neoplasms. PitNETscan be classified in non-secretory, clinically non-functioning pituitary adenomas (NFPAs), and secretory, comprising prolactin (PRL), growth hormone (GH) and adrenocoticotropic hormone (ACTH) PitNETs. Surgical resectionis the first line treatment for PitNETs, whereas chemotherapy and radiotherapy are pr...